Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yeztugo
Pharma
Gilead's Yeztugo faces growth outlook questions
Despite Yeztugo's quarterly revenue beat, Gilead has kept the PrEP drug's 2026 forecast unchanged at about $1 billion.
Angus Liu
Aug 5, 2026 10:44am
Gilead, Merck phase 3 data back first weekly HIV pill
Jul 21, 2026 10:00am
ViiV Healthcare launches ‘PrEP Wisdom’ campaign
Jun 1, 2026 9:45am
Gilead says long-acting PrEP Yeztugo in line for $1B in '26 sales
May 8, 2026 11:30am
MSF decries Gilead's updated global access plan for Yeztugo
Apr 15, 2026 12:14pm
Manufacturing is key to Gilead's Yeztugo PrEP rollout: exec
Mar 13, 2026 10:33am
